Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 80 Colonic Neoplasms 18 Neoplasm Metastasis 17 Rectal Neoplasms 14 Neoplasms 13 Stomach Neoplasms 7 Carcinoma, Non-Small-Cell Lung 5 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Lung Neoplasms 4 Gastrointestinal Neoplasms 4 Carcinoma, Renal Cell 3 Carcinoma, Neuroendocrine 3 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myeloid, Acute 2 Breast Neoplasms 2 Brain Neoplasms 2 Adenocarcinoma 2 Urinary Bladder Neoplasms 1 Unresectable Metastatic Colorectal Cancer 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Ras-mutated Metastatic Colorectal Cancer 1 Prostatic Neoplasms 1

Interventions

Nivolumab 20 Ipilimumab 10 Paclitaxel 7 linrodostat 6 Standard of Care 6 Sirolimus 5 Gemcitabine 5 Bevacizumab 5 temsirolimus 4 relatlimab 4 Pemetrexed 4 Docetaxel 4 Carboplatin 4 ARRY-334543 4 Vorinostat 3 Erlotinib Hydrochloride 3 Dasatinib 3 Cetuximab 3 regorafenib 2 olaparib 2 apatinib 2 anlotinib 2 abemaciclib 2 Trastuzumab 2 Surveys and Questionnaires 2 Sunitinib 2 Sorafenib 2 Olanzapine 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Magnetic Resonance Spectroscopy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Advanced Cancer × IFL protocol × Clear all

NCT05605509 2026-02-06

RP-6306 in Patients With Advanced Cancer

Canadian Cancer Trials Group

Phase 2 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡